Stallergenes wins U.S. go-ahead for Oralair allergy pill

CHICAGO/PARIS (Reuters) - France's Stallergenes has received U.S. regulatory approval to sell the first immunotherapy pill against grass allergies in the world's biggest pharmaceutical market, sending its shares up 6 percent on Wednesday. Stallergenes has said it sees a potential U.S. market of nearly 3 million patients that will eventually be worth $1 billion in annual sales for these types of drugs. Oralair is a fast-dissolving tablet to be placed under the tongue that contains extracts from five types of grass pollen: sweet vernal, orchard, perennial rye, timothy and Kentucky bluegrass. In December, both drugs received strong recommendations from outside advisers to the U.S. Food and Drug Administration (FDA).



via Health News Headlines - Yahoo News http://ift.tt/QEXpvp